BCL2 and metastatic melanoma: A randomized clinical trial for metastatic melanoma comparing dacarbazine alone with dacarbazine and Bcl-2 antisense demonstrated an increase in response rates and improved survival in patients with less aggressive disease, but not in patients with more aggressive disease (as assessed by levels of lactate dehydrogenase (LDH) [78].